{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:15:34Z","timestamp":1790709334594,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jacl.2025.08.015","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:22:40Z","timestamp":1755825760000},"page":"1463-1467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Statin use in transthyretin amyloid cardiomyopathy: Assessing tolerability and drug interaction risks with tafamidis"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-3685","authenticated-orcid":false,"given":"Azita H.","family":"Talasaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret O.","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10038","key":"10.1016\/j.jacl.2025.08.015_bib0001","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jacl.2025.08.015_bib0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.015_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2013an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.015_bib0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.015_bib0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.115.066795","article-title":"Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with Rosuvastatin by causing up to a 2-fold increase in statin exposure","volume":"44","author":"Elsby","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2025.08.015_bib0006","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association's Safety Task F. A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"17","key":"10.1016\/j.jacl.2025.08.015_bib0007","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacl.2025.08.015_bib0008","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.jacl.2025.08.015_bib0009","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.015_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jacl.2024.09.005","article-title":"Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: an expert clinical consensus from the National Lipid Association and the American Geriatrics Society","volume":"19","author":"Bittner","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.015_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.015_bib0012","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.jacl.2025.08.015_bib0013","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.015_bib0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/15269248251349768","article-title":"Safety of concomitant use of Tacrolimus and high-intensity statins in liver and kidney transplant recipients","volume":"35","author":"Klein","year":"2025","journal-title":"Prog Transplant"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.015_bib0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/ijms19030855","article-title":"Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions","volume":"19","author":"Alam","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jacl.2025.08.015_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16111371","article-title":"Bempedoic acid, the first-in-class oral ATP citrate lyase inhibitor with hypocholesterolemic activity: clinical pharmacology and drug-drug interactions","volume":"16","author":"Ferri","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jacl.2025.08.015_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejim.2019.05.002","article-title":"Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients","volume":"65","author":"Gallo","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"15","key":"10.1016\/j.jacl.2025.08.015_bib0018","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jaccas.2020.09.037","article-title":"Rhabdomyolysis in the setting of concomitant use of Tafamidis, Atorvastatin, and Amiodarone","volume":"2","author":"Laird","year":"2020","journal-title":"JACC Case Rep"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.015_bib0019","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jacl.2022.10.003","article-title":"A stepwise approach to prescribing novel lipid-lowering medications","volume":"16","author":"Kakavand","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.015_bib0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-025-02159-z","article-title":"Acoramidis: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:49:56Z","timestamp":1772894996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1933287425003782"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.08.015","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin use in transthyretin amyloid cardiomyopathy: Assessing tolerability and drug interaction risks with tafamidis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}